Holding more than 25 years of experience in the life sciences sector, Mr. Béraud has particularly acquired a solid expertise in business development. With a background in sales and marketing within multinationals in the field of clinical diagnostic, his career path has led him to assume responsibility for business development for an SME in the domain of biotechnology, in addition to working as a consultant within the industry as well as a technology transfer organization. Mr. Béraud has also worked on managing the policies and strategic development of an industrial association in the life sciences sector before joining Montréal InVivo’s team. Highly socially engaged with schools and the health community, he currently chairs on the board of a community organization working towards the social and economic reintegration of individuals in situations of homelessness in Montreal (Le Sac à Dos).
Dr. Marie-Josée Hébert is Professor of Medicine at the Faculty of Medicine at Université de Montréal, researcher at the CHUM research centre and nephrologist–transplant physician at CHUM. She holds the Shire Chair in Renal Transplantation and Regeneration at the Université de Montréal. Dr Hébert is the co-director of the Canadian National Transplant Research Program (CNTRP). Dr. Hébert has been appointed Vice-rector – Research, Discovery, Creation and Innovation at Université de Montréal in November 2015. As such, she assumes the coordination of all UdeM research activities at the local, national and international levels. Her mandate also includes creation activities which involves many faculties at UdeM.
Paul Lirette assumed his role as President, Canada Pharmaceuticals in June 2012 and is responsible for all pharmaceutical operations for GSK in Canada. He currently sits on the Canadian Country Management Board representing the Pharma business as well as being a prominent member of the Pharma Leadership Team. A native of Montreal, Paul has 25 years of industry experience and has held international leadership roles with GSK in both Europe and Australia. Since 2012, Paul has been an active member of both Canada’s Research-Based Pharmaceutical Companies (Rx&D) sitting on the Board of Directors and with Montreal InVivo as part of their Administrative Committee. In November 2013, Paul became the Chairman of the Québec Committee of Rx&D and in June 2014 he was appointed as Chairman of the Board of Directors of Montreal InVivo. Previously, Paul was based in the UK and served as Senior Vice President at GlaxoSmithKline and Area Director for Central Europe from 2008-2012. During this time, Paul also served as Chairman of the Central and Eastern European Task Force for the European Federation of Pharmaceutical Industries and Associations (EFPIA). As GSK’s Australasia Area Director and General Manager from 2005-2008, Paul had oversight of the company’s operations in Australia and New Zealand. In 2001, Paul was appointed Vice President of Sales & Marketing at GSK in Canada, where he led the company’s national sales operations and strategic marketing initiative for four years. Mr. Lirette holds an MBA from the Université de Sherbrooke and a Bachelor’s degree in Business Management from the Université du Québec à Montréal.
Very active in the Québec scientific environment, Dr. Jacques Gagné has been Chairman of the Boeard of CQIB, the incubator in life sciences. He has also been President of Prix Galien Canada and President of the Scientific Committee of La Fête champêtre of the Armand-Frappier Foundation. He has had a long and fruitful career. He has been Administrator and Vice president of the Ordre des pharmaciens du Québec, President of the Associstion of the Faculties of Pharmacy of Canada as well as President of the Association of Deans of Pharmacy of Canada. He was Director general and founder of the Institute forv Research in Industrial Pharmacy. He served as a consultant for the Ministère de la santé et des services sociaux du Québec. He has been a founding member and Secretary of Pharma Vision Québec. He also was the founding Executive Director of the Frosst Healthcare Foundation and Chairman of the board of Pharmagène and URRMA. He was a Director of Warnex Inc.. He holds a B.Sc. (Pharmacy), an M.Sc and a Ph.D. in Pharmacology from the Université de Montréal. He was granted a Fellowship from the Medical Research of Canada for a post-doctoral training at the Faculty of Pharmacy at the University of California San Francisco. He has been Professor and Dean of the Faculty of Pharmacy at the Université de Montréal. He his an active member of several professional and scientific organizations. He actively participated in the organization of national as well as international meetings. He acts as a consultant to public and private societies, especially in the areas of biotechnologu and pharmacy.
A co‐founder of Caprion, Martin has led the development of Caprion's leading proteomics technology and of its profitable and rapidly growing service business in the field of drug discovery and personalized medicine. Under his leadership as CEO since 2007, Caprion has achieved a 3–fold increase in revenues and a 20‐fold increase in operating profits by building successful customer relationships and strategic alliances with over 50 major pharmaceutical and biotechnology companies as well as with leading government agencies and academic institutions. He also concluded two successful acquisitions as well as the recent sale of Caprion to Chicago Growth Partners, a leading healthcare private equity firm. Prior to Caprion, Martin began his professional career as a management consultant with McKinsey & Company. He then initiated his career as a biotech entrepreneur at Advanced Bioconcept, initially as Vice‐President of Sales & Marketing and then as General Manager following the company's acquisition by NEN Life Sciences (now part of Perkin‐Elmer). Martin is currently a member of the Governing Council of the Canadian Institutes of Health Research (CIHR), and of the Board of Directors of Cytovance Biologics, Mispro Biotech services, Montreal In‐Vivo and the Atlantic Cancer Research Institute. Martin earned his bachelor's degree in Economics from the University of Moncton prior to completing an M.A. in Economics and Politics at Oxford University as a Rhodes Scholar.
Pierre Falardeau joined Verlyx Pharma in January 2010, as President and Chief Executive Officer. Dr. Falardeau has broad experience in drug development acquired over several years in the field of oncology. He is the founder of Consultation Pharm-Asset Inc., a consultation services in decision-support committed to delivering evidence-based business guidance to support global success in the pharmaceutical and biopharmaceutical industry, including financing strategy, portfolio optimization and product development. From 2002 to 2007, Dr. Falardeau was President and Chief Executive Officer of Ecopia Biosciences Inc., until the merger of Ecopia with Caprion Pharmaceutical to form Thallion Pharmaceuticals, of which Dr. Falardeau became the Chief Operating Officer until 2009. From 1998 to 2002, he held increasingly responsible positions at Æterna-Zentaris, first as Director, Scientific Affairs, then as Vice-President, Scientific Affairs, with a focus in oncology. From 1987 to 1991, Dr. Falardeau did his post-doctoral training at the Howard Hughes Medical Institute at Duke University, in Durham, North Carolina. Dr. Falardeau obtained his PhD in pharmacology and physiology in 1987 at Laval University, in Quebec City. Dr. Falardeau is a member of the board of directors of several companies and organizations in the life sciences sector.